{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:12:26Z","timestamp":1790266346909,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-HH202103-0373"],"award-info":[{"award-number":["Y-HH202103-0373"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xcrm.2025.102482","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:54:10Z","timestamp":1764863650000},"page":"102482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"6","author":[{"given":"Bin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3184-9907","authenticated-orcid":false,"given":"Wanguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102482_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102482_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102482_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102482_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102482_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1128930","article-title":"Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy","volume":"13","author":"Casadei-Gardini","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102482_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102482_bib9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102482_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102482_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810869","article-title":"IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?","volume":"23","author":"Brandi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102482_bib14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.21873\/invivo.11798","article-title":"Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis","volume":"34","author":"Rizzo","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.xcrm.2025.102482_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00432-022-04485-1","article-title":"Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis","volume":"149","author":"He","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib18","first-page":"6584","article-title":"Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma","volume":"12","author":"Hu","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.xcrm.2025.102482_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266707","article-title":"Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma","volume":"17","author":"Ishii","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102482_bib20","article-title":"Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinoma in vitro and in tumor models","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102482_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00262-024-03677-7","article-title":"Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric\/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102482_bib22","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1002\/cncr.33803","article-title":"A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102482_bib23","first-page":"145","article-title":"Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma","volume":"31","author":"Song","year":"2024","journal-title":"Diagn. Interv. Radiol."},{"key":"10.1016\/j.xcrm.2025.102482_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102482_bib25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2025.102482_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114046","article-title":"Unresectable biliary tract cancer: Current and future systemic therapy","volume":"203","author":"Zhang","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102482_bib27","article-title":"New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg. Health. Eur."},{"key":"10.1016\/j.xcrm.2025.102482_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102482_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","article-title":"Immune checkpoint therapy in liver cancer","volume":"37","author":"Xu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102482_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102482_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102482_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.xcrm.2025.102482_bib33","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/liv.15366","article-title":"KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression","volume":"42","author":"Tanaka","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.xcrm.2025.102482_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102482_bib35","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.xcrm.2025.102482_bib36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/modpathol.2017.22","article-title":"Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas","volume":"30","author":"Akita","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.xcrm.2025.102482_bib37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis","volume":"68","author":"Bas","year":"2025","journal-title":"Clin. Nutr. ESPEN"},{"key":"10.1016\/j.xcrm.2025.102482_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4939-9773-2_5","article-title":"Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing","volume":"2055","author":"Bonneville","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102482_bib39","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1038\/s41467-022-31780-9","article-title":"Landscape of somatic alterations in large-scale solid tumors from an Asian population","volume":"13","author":"Wu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102482_bib40","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102482_bib41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102482_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111541","article-title":"Comparison of efficacy and safety of conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization in unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective cohort study","volume":"176","author":"Zhang","year":"2024","journal-title":"Eur. J. Radiol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:54:43Z","timestamp":1790265283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666379125005555"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102482","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102482"}}